واکسن کووید-۱۹ (Persian Wikipedia)

Staff, Agencia EFE (31 December 2020). "La República Dominicana aprueba la vacuna de AstraZeneca contra la covid-19". Agencia EFE (به اسپانیایی). Archived from the original on 24 January 2021. Retrieved 27 January 2021.

emirateswoman.com

"Dubai approves the Pfizer-BioNTech vaccine which will be free of charge". Emirates Woman. 23 December 2020. Retrieved 28 December 2020.

europa.eu

ec.europa.eu

"Questions and Answers: COVID-19 vaccination in the EU". کمیسیون اروپا. 21 December 2020. Retrieved 21 December 2020.
"Comirnaty". Union Register of medicinal products. Retrieved 8 January 2021.
"European Commission authorises second safe and effective vaccine against COVID-19". European Commission (Press release). Retrieved 6 January 2021.
"COVID-19 Vaccine Moderna". Union Register of medicinal products. Retrieved 14 January 2021.

ema.europa.eu

"Comirnaty EPAR". آژانس دارویی اروپا (EMA). Retrieved 23 December 2020.
"COVID-19 Vaccine Moderna EPAR". آژانس دارویی اروپا (EMA). Retrieved 20 January 2021.
"EMA recommends COVID-19 Vaccine Moderna for authorisation in the EU" (Press release). European Medicines Agency. 6 January 2021. Retrieved 6 January 2021.

fda.gov

FDA Review of Efficacy and Safety of Pfizer-BioNTech COVID-19 Vaccine Emergency Use Authorization Request (PDF). U.S. سازمان غذا و دارو (آمریکا) (FDA) (Report). 10 December 2020. Retrieved 11 December 2020. This article incorporates text from this source, which is in the public domain.
"FDA Takes Key Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for First COVID-19 Vaccine" (Press release). U.S. سازمان غذا و دارو (آمریکا) (FDA). 11 December 2020. Retrieved 11 December 2020. This article incorporates text from this source, which is in the public domain.
"Pfizer-BioNTech COVID-19 Vaccine EUA Fact Sheet for Healthcare Providers" (PDF). Pfizer. 11 December 2020.
"FDA Takes Additional Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for Second COVID-19 Vaccine". U.S. سازمان غذا و دارو (آمریکا) (FDA) (Press release). Retrieved 18 December 2020.

financialexpress.com

"Covid-19 vaccine: Serum Institute signs up for 100 million doses of vaccines for India, low and middle-income countries". The Financial Express. 7 August 2020.

france24.com

"Jordan approves Pfizer-BioNTech Covid vaccine". France 24. 15 December 2020. Retrieved 15 December 2020.
https://www.france24.com/es/minuto-a-minuto/20210120-chile-aprueba-el-uso-de-emergencia-de-la-vacuna-china-de-sinovac-contra-covid-19

gennova.bio

"mRNA Vaccines – HGC019". Gennova Biopharmaceuticals Limited. Retrieved 13 January 2021.

go.com

abcnews.go.com

"Turkish official says CoronaVac vaccine 91.25% effective". ABC News. Associated Press. Retrieved 28 December 2020.

gov.uk

"UK medicines regulator gives approval for first UK COVID-19 vaccine". Medicines and Healthcare Products Regulatory Agency, Government of the UK. 2 December 2020. Retrieved 2 December 2020.
"Information for Healthcare Professionals on Pfizer/BioNTech COVID-19 vaccine". Medicines & Healthcare products Regulatory Agency (MHRA). 8 December 2020. Retrieved 13 December 2020.
"Conditions of Authorisation for Pfizer/BioNTech COVID-19 vaccine". Medicines & Healthcare products Regulatory Agency (MHRA). 3 December 2020. Retrieved 13 December 2020.
"Information for Healthcare Professionals on COVID-19 Vaccine Moderna". Medicines and Healthcare products Regulatory Agency (MHRA). 8 January 2021. Retrieved 8 January 2021.
"Conditions of Authorisation for COVID-19 Vaccine Moderna". Medicines and Healthcare products Regulatory Agency (MHRA). 8 January 2021. Retrieved 9 January 2021.
"Information for Healthcare Professionals on COVID-19 Vaccine AstraZeneca". Medicines and Healthcare products Regulatory Agency (MHRA). 30 December 2020. Retrieved 4 January 2021.
"Oxford University/AstraZeneca vaccine authorised by UK medicines regulator" (Press release). Department of Health and Social Care. 30 December 2020. Retrieved 30 December 2020.
"Conditions of Authorisation for COVID-19 Vaccine AstraZeneca". Medicines and Healthcare products Regulatory Agency (MHRA). 30 December 2020. Retrieved 4 January 2021.

gulfnews.com

"AstraZeneca and Moderna vaccines to be administered in Saudi Arabia". gulfnews.com (به انگلیسی). Retrieved 2021-01-19.

hawaiipublicradio.org

Dorman, Bill (6 January 2021). "Asia Minute: Palau Administers Vaccines to Keep Country Free of COVID". Hawaii Public Radio. Retrieved 13 January 2021.

hindustantimes.com

Kumar, Shivani (1 December 2020). "Sputnik-V from Russia arrives in India for clinal trials". Hindustan Times.

ina-registry.org

PT. Bio Farma (10 August 2020). "A Phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-COV-2 inactivated vaccine in healthy adults aged 18–59 years in Indonesia". Registri Penyakit Indonesia. Retrieved 15 August 2020.

indianexpress.com

"Clinical trial: 17 volunteers given Russia's Sputnik V Covid-19 vaccine in Pune". The Indian Express. 6 December 2020.
Raghavan, Prabha (15 December 2020). "Pune-based Gennova to begin human trials of its Covid vaccine 'soon'". The Indian Express.

indiatimes.com

economictimes.indiatimes.com

"Mexico authorizes emergency use of Pfizer-BioNTech coronavirus vaccine". The Economic Times. 12 December 2020. Retrieved 14 January 2021.
"AstraZeneca & Serum Institute of India sign licensing deal for 1 million doses of Oxford vaccine". The Economic Times. Retrieved 15 June 2020.
Thacker, Teena. "Zydus Cadila to test ZyCoV-D on 30,000 patients in Phase-3 trials". The Economic Times. Retrieved 16 December 2020.

ivi.int

"IVI, INOVIO, and KNIH to partner with CEPI in a Phase I/II clinical trial of INOVIO's COVID-19 DNA vaccine in South Korea". International Vaccine Institute. 16 April 2020. Retrieved 23 April 2020.
"Genexine consortium's Covid-19 vaccine acquires approval for clinical trails in Korea". 11 June 2020. Retrieved 1 August 2020.

jpost.com

"Israeli Health Minister 'pleased' as FDA approves Pfizer COVID-19 vaccine". The Jerusalem Post. Retrieved 28 December 2020.

khaleejtimes.com

"UAE approves Russia's Sputnik vaccine for emergency use". Khaleej Times. 21 January 2021. Retrieved 21 January 2021.

laegemiddelstyrelsen.dk

"Første vaccine mod COVID19 godkendt i EU". Lægemiddelstyrelsen (به دانمارکی). Retrieved 2020-12-26.
"Endnu en vaccine mod COVID-19 er godkendt af EU-Kommissionen". Lægemiddelstyrelsen (به دانمارکی). Retrieved 2021-01-07.

lanacion.com.ar

"Coronavirus en la Argentina: La ANMAT aprobo el uso de emergencia de la vacuna Pfizer". La Nación (به اسپانیایی). Retrieved 23 December 2020.

latercera.com

Lazcano, Patricio (15 November 2020). "Así funcionan las cuatro vacunas que se probarán en Chile". La Tercera. Retrieved 15 December 2020.

legemiddelverket.no

"Status på koronavaksiner under godkjenning per 21.12.20". Statens legemiddelverk (به نروژی بوک‌مُل). Archived from the original on 8 January 2021. Retrieved 2020-12-26.
"Status på koronavaksiner under godkjenning per 6. januar 2021". Statens legemiddelverk (به نروژی بوک‌مُل). Archived from the original on 4 February 2021. Retrieved 2021-01-07.

livemint.com

"Oxford COVID-19 vaccine final trials will be held in these 17 hospitals in India". mint. 19 August 2020.
Leo, Leroy (16 November 2020). "Biological E initiates human trials of vaccine". Mint.

lyfjastofnun.is

"COVID-19: Bóluefninu Comirnaty frá BioNTech/Pfizer hefur verið veitt skilyrt íslenskt markaðsleyfi". Lyfjastofnun (به ایسلندی). Retrieved 2020-12-26.
"COVID-19: Bóluefninu COVID-19 Vaccine Moderna frá hefur verið veitt skilyrt íslenskt markaðsleyfi". Lyfjastofnun (به ایسلندی). Retrieved 2021-01-07.

merck.com

"Merck Discontinues Development of SARS-CoV-2/COVID-19 Vaccine Candidates; Continues Development of Two Investigational Therapeutic Candidates". Merck (Press release). 25 January 2021. Retrieved 25 January 2021.

milkeninstitute.org

"COVID-19 vaccine tracker (Choose vaccines tab, apply filters to view select data)". Milken Institute. 2020-11-16. Retrieved 2020-11-09. Lay summary. {{cite web}}: Cite uses deprecated parameter |lay-url= (help)

minsalud.gob.bo

"Ministerio de Salud de Bolivia - Bolivia y Rusia firman contrato para adquirir 5,2 millones de dosis de la vacuna Sputnik-V contra la COVID-19". www.minsalud.gob.bo. Retrieved 1 January 2021.

modernatx.com

investors.modernatx.com

"Moderna's COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study | Moderna, Inc". investors.modernatx.com (به انگلیسی). Archived from the original on 30 November 2020. Retrieved 2020-11-27.
"Israeli Ministry of Health Authorizes COVID-19 Vaccine Moderna for Use in Israel". modernatx.com. 4 January 2021. Archived from the original on 17 February 2021. Retrieved 4 January 2021.

msn.com

"Iraq grants emergency approval for Pfizer COVID-19 vaccine". MSN. Retrieved 27 December 2020.
Lim, Ida (2021-01-08). "Khairy: Malaysia can use Pfizer's Covid-19 vaccine now as conditional registration granted". Malay Mail. Retrieved 2021-01-08.
"Bahrain allows Sinopharm COVID-19 vaccine candidate use in frontline workers". MSN. Reuters. Retrieved 3 November 2020.

n1info.com

rs.n1info.com

"Agencija odobrila uvoz ruske vakcine Sputnjik V u Srbiju". N1 (به صربی). 31 December 2020.

nationalpost.com

Chander, Vishwadha (14 July 2020). "Canada's Medicago begins human trials of plant-based COVID-19 vaccine". National Post. Reuters. Archived from the original on 1 November 2020. Retrieved 14 July 2020.

nature.com

Mullard, Asher (2020-11-30). "How COVID vaccines are being divvied up around the world". Nature (به انگلیسی). doi:10.1038/d41586-020-03370-6.
Thanh Le, Tung; Andreadakis, Zacharias; Kumar, Arun; Gómez Román, Raúl; Tollefsen, Stig; Saville, Melanie; Mayhew, Stephen (9 April 2020). "The COVID-19 vaccine development landscape". Nature Reviews Drug Discovery. 19 (5): 305–306. doi:10.1038/d41573-020-00073-5. ISSN 1474-1776. PMID 32273591.

ndtv.com

"Bharat Biotech Recruits 23,000 Volunteers For Covaxin's Phase 3 Clinical Trial". NDTV.com. 28 December 2020. Retrieved 3 January 2021.

newagebd.net

"Globe Biotech seeks approval for vaccine trials". newagebd.net. New Age. 17 January 2021.

nih.gov

pubmed.ncbi.nlm.nih.gov

Diamond, Michael S; Pierson, Theodore C (2020-05-13). "The challenges of vaccine development against a new virus during a pandemic". Cell Host and Microbe. 27 (5): 699–703. doi:10.1016/j.chom.2020.04.021. PMC 7219397. PMID 32407708.
So, Anthony D; Woo, Joshua (2020-12-15). "Reserving coronavirus disease 2019 vaccines for global access: cross sectional analysis". The BMJ. 371. doi:10.1136/bmj.m4750. ISSN 0959-8138. PMC 7735431. PMID 33323376.
Le, Tung Thanh; Cramer, Jakob P.; Chen, Robert; Mayhew, Stephen (2020-09-04). "Evolution of the COVID-19 vaccine development landscape". Nature Reviews Drug Discovery. 19 (10): 667–68. doi:10.1038/d41573-020-00151-8. ISSN 1474-1776. PMID 32887942. S2CID 221503034.
Thanh Le, Tung; Andreadakis, Zacharias; Kumar, Arun; Gómez Román, Raúl; Tollefsen, Stig; Saville, Melanie; Mayhew, Stephen (9 April 2020). "The COVID-19 vaccine development landscape". Nature Reviews Drug Discovery. 19 (5): 305–306. doi:10.1038/d41573-020-00073-5. ISSN 1474-1776. PMID 32273591.
Polack F, Thomas S, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. (December 2020). "Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine". New England Journal of Medicine. 383 (27): 2603–2615. doi:10.1056/NEJMoa2034577. PMC 7745181. PMID 33301246.
Mulligan, Mark J.; Lyke, Kirsten E.; Kitchin, Nicholas; Absalon, Judith; Gurtman, Alejandra; Lockhart, Stephen; et al. (October 2020). "Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults". Nature. 586 (7830): 589–593. doi:10.1038/s41586-020-2639-4. PMID 32785213. S2CID 221126922.
Baden L, Essink B, Kotloff K, Frey S, Novak R, Diemert D, et al. (December 2020). "Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine". New England Journal of Medicine. doi:10.1056/NEJMoa2035389. PMID 33378609.
Widge, Alicia T.; Rouphael, Nadine G.; Jackson, Lisa A.; Anderson, Evan J.; Roberts, Paul C.; Makhene, Mamodikoe; et al. (3 December 2020). "Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination". New England Journal of Medicine. Massachusetts Medical Society. doi:10.1056/nejmc2032195. ISSN 0028-4793. PMC 7727324. PMID 33270381.
Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al. (mRNA-1273 Study Group) (July 2020). "An mRNA Vaccine against SARS-CoV-2 – Preliminary Report". New England Journal of Medicine. 383 (20): 1920–1931. doi:10.1056/NEJMoa2022483. PMC 7377258. PMID 32663912. Lay summary. {{cite journal}}: Cite uses deprecated parameter |lay-url= (help)
Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al. (mRNA-1273 Study Group) (July 2020). "An mRNA Vaccine against SARS-CoV-2 – Preliminary Report Supplementary appendix". New England Journal of Medicine. doi:10.1056/NEJMoa2022483. PMID 32663912.
Oliver, Sara E.; Gargano, Julia W.; Marin, Mona; Wallace, Megan; Curran, Kathryn G.; Chamberland, Mary; et al. (December 2020). "The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Moderna COVID-19 Vaccine —ایالات متحده، December 2020" (PDF). MMWR. Morbidity and Mortality Weekly Report. 69 (5152): 1653–1656. doi:10.15585/mmwr.mm695152e1. PMID 33382675.
Folegatti, Pedro M; Ewer, Katie J; Aley, Parvinder K; Angus, Brian; Becker, Stephan; Belij-Rammerstorfer, Sandra; et al. (July 2020). "Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial". Lancet. 396 (10249): 467–78. doi:10.1016/S0140-6736(20)31604-4. PMC 7445431. PMID 32702298. Lay summary. {{cite journal}}: Cite uses deprecated parameter |lay-url= (help)
Logunov, Denis Y; Dolzhikova, Inna V; others (2020). "Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia". The Lancet. 396 (10255): 887–97. doi:10.1016/s0140-6736(20)31866-3. ISSN 0140-6736. PMC 7471804. PMID 32896291. S2CID 221472251.
Burki TK (November 2020). "The Russian vaccine for COVID-19". The Lancet. Respiratory Medicine. 8 (11): e85–e86. doi:10.1016/S2213-2600(20)30402-1. PMID 32896274.
Xia S, Duan K, Zhang Y, Zhao D, et al. (13 August 2020). "Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials". JAMA. 324 (10): 951–960. doi:10.1001/jama.2020.15543. PMC 7426884. PMID 32789505.
Zhang, Yanjun; Zeng, Gang; Pan, Hongxing; Li, Changgui; Hu, Yaling; Chu, Kai; et al. (November 2020). "Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial". The Lancet Infectious Diseases. 0. doi:10.1016/S1473-3099(20)30843-4. PMID 33217362. S2CID 227099817.
Zhu, Feng-Cai; Guan, Xu-Hua; Li, Yu-Hua; Huang, Jian-Ying; Jiang, Tao; Hou, Li-Hua; et al. (July 2020). "Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial". Lancet. 396 (10249): 479–88. doi:10.1016/s0140-6736(20)31605-6. ISSN 0140-6736. PMID 32702299. Lay summary. {{cite journal}}: Cite uses deprecated parameter |lay-url= (help)
Sadoff J, Shukarev G, Heerwegh D, Truyers C, Leroux-Roels I, LeGars M, et al. (January 2021). "Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine". New England Journal of Medicine. doi:10.1056/NEJMoa2034201. PMID 33440088.
Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S, et al. (September 2020). "Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine". The New England Journal of Medicine. 383 (24): 2320–2332. doi:10.1056/NEJMoa2026920. PMC 7494251. PMID 32877576.
Rawat, Kajal; Kumari, Puja; Saha, Lekha (24 November 2020). "COVID-19 vaccine: A recent update in pipeline vaccines, their design and development strategies". European Journal of Pharmacology. 892: 173751. doi:10.1016/j.ejphar.2020.173751. ISSN 1879-0712. PMC 7685956. PMID 33245898.

ncbi.nlm.nih.gov

Diamond, Michael S; Pierson, Theodore C (2020-05-13). "The challenges of vaccine development against a new virus during a pandemic". Cell Host and Microbe. 27 (5): 699–703. doi:10.1016/j.chom.2020.04.021. PMC 7219397. PMID 32407708.
So, Anthony D; Woo, Joshua (2020-12-15). "Reserving coronavirus disease 2019 vaccines for global access: cross sectional analysis". The BMJ. 371. doi:10.1136/bmj.m4750. ISSN 0959-8138. PMC 7735431. PMID 33323376.
Polack F, Thomas S, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. (December 2020). "Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine". New England Journal of Medicine. 383 (27): 2603–2615. doi:10.1056/NEJMoa2034577. PMC 7745181. PMID 33301246.
Widge, Alicia T.; Rouphael, Nadine G.; Jackson, Lisa A.; Anderson, Evan J.; Roberts, Paul C.; Makhene, Mamodikoe; et al. (3 December 2020). "Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination". New England Journal of Medicine. Massachusetts Medical Society. doi:10.1056/nejmc2032195. ISSN 0028-4793. PMC 7727324. PMID 33270381.
Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al. (mRNA-1273 Study Group) (July 2020). "An mRNA Vaccine against SARS-CoV-2 – Preliminary Report". New England Journal of Medicine. 383 (20): 1920–1931. doi:10.1056/NEJMoa2022483. PMC 7377258. PMID 32663912. Lay summary. {{cite journal}}: Cite uses deprecated parameter |lay-url= (help)
Folegatti, Pedro M; Ewer, Katie J; Aley, Parvinder K; Angus, Brian; Becker, Stephan; Belij-Rammerstorfer, Sandra; et al. (July 2020). "Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial". Lancet. 396 (10249): 467–78. doi:10.1016/S0140-6736(20)31604-4. PMC 7445431. PMID 32702298. Lay summary. {{cite journal}}: Cite uses deprecated parameter |lay-url= (help)
Logunov, Denis Y; Dolzhikova, Inna V; others (2020). "Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia". The Lancet. 396 (10255): 887–97. doi:10.1016/s0140-6736(20)31866-3. ISSN 0140-6736. PMC 7471804. PMID 32896291. S2CID 221472251.
Xia S, Duan K, Zhang Y, Zhao D, et al. (13 August 2020). "Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials". JAMA. 324 (10): 951–960. doi:10.1001/jama.2020.15543. PMC 7426884. PMID 32789505.
Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S, et al. (September 2020). "Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine". The New England Journal of Medicine. 383 (24): 2320–2332. doi:10.1056/NEJMoa2026920. PMC 7494251. PMID 32877576.
Rawat, Kajal; Kumari, Puja; Saha, Lekha (24 November 2020). "COVID-19 vaccine: A recent update in pipeline vaccines, their design and development strategies". European Journal of Pharmacology. 892: 173751. doi:10.1016/j.ejphar.2020.173751. ISSN 1879-0712. PMC 7685956. PMID 33245898.

nih.gov

"Promising Interim Results from Clinical Trial of NIH-Moderna COVID-19 Vaccine". National Institutes of Health (NIH). 15 November 2020.

nikkei.com

asia.nikkei.com

"CanSino's COVID-19 vaccine approved for military use in China". Nikkei Asia. Archived from the original on 7 March 2021. Retrieved 24 December 2020.

npr.org

Palca, Joe (27 July 2020). "COVID-19 vaccine candidate heads to widespread testing in U.S." NPR. Archived from the original on 11 October 2020. Retrieved 27 July 2020.

nst.com.my

Ying, Teoh Pei (7 December 2020). "MYEG to conduct phase 3 clinical trial for China's Covid-19 vaccine in Msia | New Straits Times". New Straits Times. Retrieved 28 December 2020.

nytimes.com

Zimmer, Carl; Corum, Jonathan; Wee, Sui-Lee (10 June 2020). "Coronavirus Vaccine Tracker". نیویورک تایمز. ISSN 0362-4331. Retrieved 12 December 2020.
Schmall, Emily; Yasir, Sameer (3 January 2021). "India Approves Oxford-AstraZeneca Covid-19 Vaccine and 1 Other". The New York Times. Retrieved 3 January 2021.
Wee, Sui-Lee; Qin, Amy (2020-12-30). "A Chinese Covid-19 Vaccine Has Proved Effective, Its Maker Says". The New York Times. ISSN 0362-4331. Retrieved 2020-12-30.
Wee, Sui-Lee (9 December 2020). "Chinese Covid-19 Vaccine Gets Key Push, but Doubts Swirl". نیویورک تایمز. Retrieved 12 December 2020.

oreanda.ru

"Russian EpiVacCorona Vaccine Has No Adverse Effects". OREANDA-NEWS. 13 January 2021.

orient.tm

"Turkmenistan is the first in Central Asia to have registered "Sputnik V» vaccine". Orient (به انگلیسی). 18 January 2021. Archived from the original on 27 January 2021. Retrieved 27 January 2021.

ourworldindata.org

«Coronavirus (COVID-19) Vaccinations - Statistics and Research». Our World in Data. دریافت‌شده در ۲۰۲۱-۰۶-۱۶.

ox.ac.uk

research.ox.ac.uk

"Oxford University breakthrough on global COVID-19 vaccine". www.research.ox.ac.uk (به انگلیسی).

pattayamail.com

https://www.pattayamail.com/thailandnews/thai-food-and-drug-registers-covid-19-vaccine-developed-by-astrazeneca-341186

pfizer.com

"Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study". Pfizer. Retrieved 9 November 2020.
"Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints". Pfizer. 18 November 2020.

pib.gov.in

"DBT-BIRAC supported indigenously developed DNA Vaccine Candidate by Zydus Cadila, approved for Phase III clinical trials". pib.gov.in. Press Information Bureau. 3 January 2021.
"Indigenous mRNA vaccine candidate supported by DBT gets Drug Controller nod to initiate Human clinical trials". pib.gov.in. Press Information Bureau. Retrieved 13 January 2021.

plenglish.com

"Cuban scientists start second phase of Soberana 02 vaccine". Prensa Latina. 22 December 2020. Retrieved 22 January 2021.

pmlive.com

"GSK, Medicago launch phase 2/3 clinical trials of plant-derived COVID-19 vaccine". PMLive. 13 November 2020. Retrieved 16 November 2020.

precisionvaccinations.com

"VLA2001 COVID-19 Vaccine". Precision Vaccinations. 31 December 2020. Retrieved 11 January 2021.
"UQ-CSL V451 Vaccine". precisionvaccinations.com. Archived from the original on 19 December 2020. Retrieved 11 December 2020.

rdif.ru

"Palestine has become the first country in the Middle East to register Sputnik V vaccine". RFID. 11 January 2021. Archived from the original on 5 February 2021. Retrieved 27 January 2021.

reuters.com

Erman, Michael (18 November 2020). "Pfizer ends COVID-19 trial with 95% efficacy, to seek emergency-use authorization". Reuters. Retrieved 18 November 2020.
"Oman issues licence to import Pfizer BioNTech Covid vaccine – TV". Reuters. 15 December 2020. Retrieved 16 December 2020.
"Qatar, Oman to receive Pfizer-BioNTech COVID-19 vaccine this week". Reuters. Retrieved 24 December 2020.
"Argentine regulator approves AstraZeneca/Oxford COVID-19 vaccine". Reuters. 30 December 2020. Retrieved 30 December 2020.
McGeever, Jamie; Fonseca, Pedro (17 January 2021). "Brazil clears emergency use of Sinovac, AstraZeneca vaccines, shots begin". Reuters. Retrieved 17 January 2021.
https://www.reuters.com/article/health-coronavirus-ecuador-astrazeneca/ecuador-approves-use-of-astrazeneca-vaccine-for-covid-19-idUSL1N2JZ0HC
"El Salvador greenlights AstraZeneca, Oxford University COVID-19 vaccine". Reuters. 30 December 2020.
"Hungarian drug regulator approves Sputnik V vaccine: website". Reuters. 21 January 2021.
"Mexico approves AstraZeneca COVID-19 vaccine, minister says". Reuters. 5 January 2021. Retrieved 14 January 2021.
Staff, Reuters (15 January 2021). "Nepal approves AstraZeneca COVID vaccine for emergency use - government statement". Reuters (به انگلیسی).
Staff, Reuters (16 January 2021). "Pakistan approves AstraZeneca COVID-19 vaccine for emergency use" (به انگلیسی).
"Belarus registers Sputnik V vaccine, in first outside Russia - RDIF". Reuters. 21 December 2020. Retrieved 22 December 2020.
"Iran approves Russian coronavirus vaccine Sputnik V". Reuters. 26 January 2021.
"Paraguay approves Russia's Sputnik V vaccine: RDIF". Reuters. 15 January 2021. Retrieved 15 January 2021.
"Venezuela firma contrato para la adquisición de la vacuna rusa Sputnik V" (به اسپانیایی). Reuters. 29 December 2020.
https://www.reuters.com/article/health-coronavirus-pakistan-sinopharm/pakistan-approves-chinese-sinopharm-covid-19-vaccine-for-emergency-use-idUSKBN29O049
Martinez, Ana Isabel (3 November 2020). "CanSino Biologics delivers COVID-19 vaccine to Mexico for late-stage trial". Reuters. Retrieved 4 November 2020.
Nafisa, Eltahir (9 August 2020). "CanSino to start Phase III trial of COVID-19 vaccine in Saudi". Reuters. Retrieved 4 November 2020.
"S. Korea's Genexine begins human trial of coronavirus vaccine". Reuters. 19 June 2020. Archived from the original on 11 October 2020. Retrieved 25 June 2020.

in.reuters.com

"Colombia regulator approves Pfizer-BioNTech vaccine for emergency use". رویترز. 6 January 2021. Archived from the original on 8 January 2021. Retrieved 6 January 2021.

rferl.org

https://www.rferl.org/a/serbia-covid-vaccine-china-sinopharm/31053091.html

rospotrebnadzor.ru

"О регистрации вакцины ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора «ЭпиВакКорона»". Rospotrebnadzor (به روسی). 14 October 2020. Archived from the original on 1 November 2020. Retrieved 27 January 2021.

royanews.tv

en.royanews.tv

"First batch of Chinese Sinopharm vaccine arrives in Jordan". Roya News. Retrieved 9 January 2021.

saudigazette.com.sa

https://saudigazette.com.sa/article/602862

sciencealert.com

Grenfell, Rob; Drew, Trevor (17 February 2020). "Here's Why It's Taking So Long to Develop a Vaccine for the New Coronavirus". ScienceAlert. Archived from the original on 28 February 2020. Retrieved 26 February 2020.

sciencemag.org

blogs.sciencemag.org

Folegatti, Pedro M; Ewer, Katie J; Aley, Parvinder K; Angus, Brian; Becker, Stephan; Belij-Rammerstorfer, Sandra; et al. (July 2020). "Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial". Lancet. 396 (10249): 467–78. doi:10.1016/S0140-6736(20)31604-4. PMC 7445431. PMID 32702298. Lay summary. {{cite journal}}: Cite uses deprecated parameter |lay-url= (help)
Zhu, Feng-Cai; Guan, Xu-Hua; Li, Yu-Hua; Huang, Jian-Ying; Jiang, Tao; Hou, Li-Hua; et al. (July 2020). "Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial". Lancet. 396 (10249): 479–88. doi:10.1016/s0140-6736(20)31605-6. ISSN 0140-6736. PMID 32702299. Lay summary. {{cite journal}}: Cite uses deprecated parameter |lay-url= (help)

scmp.com

"Tests show coronavirus vaccine by China's Sinovac is safe, says Brazil's Butantan Institute". Archived from the original on 29 October 2020. Retrieved 29 October 2020.
Ng, Eric (28 October 2020). "چین's CanSino trials Covid-19 vaccine in 'high disease burden' nations". South China Morning Post. Retrieved 4 November 2020.
Pinghui, Zhuang (20 November 2020). "Fifth Chinese Covid-19 vaccine candidate ready to enter phase 3 trials". South China Morning Post. Retrieved 26 December 2020.

seenews.com

"Albania to start COVID-19 immunisation with Pfizer vaccine in Jan – report". Seenews.

semanticscholar.org

api.semanticscholar.org

Le, Tung Thanh; Cramer, Jakob P.; Chen, Robert; Mayhew, Stephen (2020-09-04). "Evolution of the COVID-19 vaccine development landscape". Nature Reviews Drug Discovery. 19 (10): 667–68. doi:10.1038/d41573-020-00151-8. ISSN 1474-1776. PMID 32887942. S2CID 221503034.
Mulligan, Mark J.; Lyke, Kirsten E.; Kitchin, Nicholas; Absalon, Judith; Gurtman, Alejandra; Lockhart, Stephen; et al. (October 2020). "Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults". Nature. 586 (7830): 589–593. doi:10.1038/s41586-020-2639-4. PMID 32785213. S2CID 221126922.
Logunov, Denis Y; Dolzhikova, Inna V; others (2020). "Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia". The Lancet. 396 (10255): 887–97. doi:10.1016/s0140-6736(20)31866-3. ISSN 0140-6736. PMC 7471804. PMID 32896291. S2CID 221472251.
Zhang, Yanjun; Zeng, Gang; Pan, Hongxing; Li, Changgui; Hu, Yaling; Chu, Kai; et al. (November 2020). "Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial". The Lancet Infectious Diseases. 0. doi:10.1016/S1473-3099(20)30843-4. PMID 33217362. S2CID 227099817.

shinyapps.io

vac-lshtm.shinyapps.io

«COVID-19 vaccine tracker». vac-lshtm.shinyapps.io. دریافت‌شده در ۲۰۲۱-۰۲-۰۱.
«COVID-19 vaccine tracker». vac-lshtm.shinyapps.io. دریافت‌شده در ۲۰۲۱-۰۶-۱۶.
"COVID-19 vaccine development pipeline (Refresh URL to update)". Vaccine Centre, London School of Hygiene and Tropical Medicine. 2020-11-16. Retrieved 2020-11-16.

sld.cu

rpcec.sld.cu

"SOBERANA 02A". Registro Público Cubano de Ensayos Clínicos. 17 December 2020. Archived from the original on 27 December 2020. Retrieved 22 January 2021.
"SOBERANA 02". Registro Público Cubano de Ensayos Clínicos. 27 October 2020. Archived from the original on 26 January 2021. Retrieved 22 January 2021.

sputnikvaccine.com

"Argentina has registered the Sputnik V vaccine based on Russian clinical trial data". sputnikvaccine.com. Retrieved 1 January 2021.

srbija.gov.rs

"First shipment of Pfizer-BioNTech vaccine arrives in Serbia". Serbian government website. 22 December 2020. Retrieved 26 December 2020.

statnews.com

Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al. (mRNA-1273 Study Group) (July 2020). "An mRNA Vaccine against SARS-CoV-2 – Preliminary Report". New England Journal of Medicine. 383 (20): 1920–1931. doi:10.1056/NEJMoa2022483. PMC 7377258. PMID 32663912. Lay summary. {{cite journal}}: Cite uses deprecated parameter |lay-url= (help)

straitstimes.com

"Chile approves Pfizer-BioNTech Covid-19 vaccine for emergency use". The Straits Times. 17 December 2020. Retrieved 17 December 2020.
Soeriaatmadja, Wahyudi (2021-01-11). "Indonesia grants emergency use approval to Sinovac's vaccine, local trials show 65% efficacy". استریتس تایمز. Retrieved 2021-01-11.

swissmedic.ch

"Swissmedic grants authorisation for the COVID-19 vaccine from Moderna" (Press release). Swiss Agency for Therapeutic Products (Swissmedic). 2020-01-12. Retrieved 2020-01-12.

szgimi.org

"About Us". Shenzhen Genoimmune Medical Institute. Archived from the original on 11 October 2020. Retrieved 1 August 2020.

tass.com

"Over 1,400 volunteers get Russia's first EpiVacCorona vaccine jab". TASS. 15 December 2020.

tempo.co

en.tempo.co

"BPOM Grants Emergency Use Authorization for Sinovac Vaccine". Tempo. 2021-01-11. Retrieved 2021-01-11.

tga.gov.au

"Comirnaty". Therapeutic Goods Administration. 25 January 2021. Archived from the original on 1 February 2021. Retrieved 25 January 2021.

thedailystar.net

"Oxford University-Astrazeneca vaccine: Bangladesh okays it for emergency use". thedailystar.net. Retrieved 2021-01-06.
"Bangavax Vaccine: Permission sought for clinical trial". thedailystar.net. The Daily Star. 18 January 2021.

theglobeandmail.com

Wu, Huizhong (6 December 2020). "چین prepares large-scale rollout of domestically-produced coronavirus vaccines". The Globe and Mail. Retrieved 7 December 2020.

theguardian.com

"Covid-19 vaccine: who are countries prioritising for first doses?". the Guardian (به انگلیسی). 2020-11-18. Retrieved 2021-02-01.

thehindu.com

"Coronavirus | Zydus Cadila gets DCGI nod to initiate Phase-3 clinical trials for COVID-19 vaccine". The Hindu. 3 January 2021.

thelancet.com

"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK – The Lancet". Retrieved 9 December 2020.
Logunov, Denis Y.; Dolzhikova, Inna V.; Shcheblyakov, Dmitry V.; Tukhvatulin, Amir I.; Zubkova, Olga V.; Dzharullaeva, Alina S.; Kovyrshina, Anna V.; Lubenets, Nadezhda L.; Grousova, Daria M.; Erokhova, Alina S.; Botikov, Andrei G. (2021-02-02). "Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia". The Lancet (به انگلیسی). 0 (0). doi:10.1016/S0140-6736(21)00234-8. ISSN 0140-6736.
Burki TK (November 2020). "The Russian vaccine for COVID-19". The Lancet. Respiratory Medicine. 8 (11): e85–e86. doi:10.1016/S2213-2600(20)30402-1. PMID 32896274.

thenationalnews.com

"Coronavirus: UAE authorises emergency use of vaccine for frontline workers". The National. Retrieved 24 November 2020.

thepharmaletter.com

"Russia's EpiVacCorona vaccine post-registration trials started". The Pharma Letter. 18 November 2020.

ticotimes.net

"Costa Rica authorizes Pfizer-BioNTech coronavirus vaccine". The Tico Times. 16 December 2020. Retrieved 16 December 2020.

timesofisrael.com

"As Israel goes vaccine-wild, will the homegrown version lose its shot?". Times of Israel. 29 December 2020. Retrieved 1 January 2021.{{cite web}}: نگهداری CS1: url-status (link)

uol.com.br

noticias.uol.com.br

"Bolívia autoriza uso de vacinas Sputnik V e CoronaVac contra covid-19". noticias.uol.com.br (به پرتغالی). Retrieved 6 January 2021.

vaxine.net

"Vaxine". Archived from the original on 11 October 2020. Retrieved 1 August 2020.

vietnamnews.vn

"VN starts injection of homegrown COVID-19 vaccine in first-stage human trial". Viet Nam News. 17 December 2020.

vov.vn

english.vov.vn

"How much does first Made-in Vietnam COVID-19 vaccine cost?". Voice of Vietnam. 11 December 2020.

walvax.com

"Company introduction". Walvax Biotechnology. Archived from the original on 11 October 2020. Retrieved 1 August 2020.

washingtonpost.com

https://www.washingtonpost.com/world/asia_pacific/coronavirus-vaccine-china-sinopharm/2020/12/30/1cc4be9e-4a62-11eb-97b6-4eb9f72ff46b_story.html

web.archive.org

"Moderna's COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study | Moderna, Inc". investors.modernatx.com (به انگلیسی). Archived from the original on 30 November 2020. Retrieved 2020-11-27.
Grenfell, Rob; Drew, Trevor (17 February 2020). "Here's Why It's Taking So Long to Develop a Vaccine for the New Coronavirus". ScienceAlert. Archived from the original on 28 February 2020. Retrieved 26 February 2020.
"Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults". ClinicalTrials.gov. کتابخانه ملی پزشکی ایالات متحده آمریکا. 30 April 2020. NCT04368728. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
"A Multi-site Phase I/II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of four Prophylactic SARS-CoV-2 RNA Vaccines Against COVID-19 Using Different Dosing Regimens in Healthy Adults". EU Clinical Trials Register. European Union. 14 April 2020. EudraCT 2020-001038-36. Archived from the original on 22 April 2020. Retrieved 22 April 2020.
"Colombia regulator approves Pfizer-BioNTech vaccine for emergency use". رویترز. 6 January 2021. Archived from the original on 8 January 2021. Retrieved 6 January 2021.
"PH authorizes Pfizer's COVID-19 vaccine for emergency use". CNN Philippines. 14 January 2021. Archived from the original on 27 February 2021. Retrieved 14 January 2021.
"Comirnaty". Therapeutic Goods Administration. 25 January 2021. Archived from the original on 1 February 2021. Retrieved 25 January 2021.
"Status på koronavaksiner under godkjenning per 21.12.20". Statens legemiddelverk (به نروژی بوک‌مُل). Archived from the original on 8 January 2021. Retrieved 2020-12-26.
"A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19". ClinicalTrials.gov. کتابخانه ملی پزشکی ایالات متحده آمریکا. 14 July 2020. NCT04470427. Archived from the original on 11 October 2020. Retrieved 27 July 2020.
Palca, Joe (27 July 2020). "COVID-19 vaccine candidate heads to widespread testing in U.S." NPR. Archived from the original on 11 October 2020. Retrieved 27 July 2020.
"Israeli Ministry of Health Authorizes COVID-19 Vaccine Moderna for Use in Israel". modernatx.com. 4 January 2021. Archived from the original on 17 February 2021. Retrieved 4 January 2021.
"Status på koronavaksiner under godkjenning per 6. januar 2021". Statens legemiddelverk (به نروژی بوک‌مُل). Archived from the original on 4 February 2021. Retrieved 2021-01-07.
Walsh, Nick; Shelley, Jo; Duwe, Eduardo; Bonnett, William (27 July 2020). "The world's hopes for a coronavirus vaccine may run in these health care workers' veins". سائو پائولو: سی‌ان‌ان. Archived from the original on 3 August 2020. Retrieved 3 August 2020.
"Investigating a Vaccine Against COVID-19". ClinicalTrials.gov. کتابخانه ملی پزشکی ایالات متحده آمریکا. 26 May 2020. NCT04400838. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
"A Phase 2/3 study to determine the efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19". EU Clinical Trials Register. European Union. 21 April 2020. EudraCT 2020-001228-32. Archived from the original on 5 October 2020. Retrieved 3 August 2020.
"A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19". ClinicalTrials.gov. کتابخانه ملی پزشکی ایالات متحده آمریکا. 12 May 2020. NCT04383574. Archived from the original on 23 August 2020. Retrieved 26 August 2020.
"Trial of Oxford COVID-19 vaccine starts in Brazil". Jenner Institute. Archived from the original on 9 September 2020. Retrieved 26 August 2020.
Staff, Agencia EFE (31 December 2020). "La República Dominicana aprueba la vacuna de AstraZeneca contra la covid-19". Agencia EFE (به اسپانیایی). Archived from the original on 24 January 2021. Retrieved 27 January 2021.
"Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19". ClinicalTrials.gov. Archived from the original on 12 September 2020. Retrieved 11 September 2020.
"Palestine has become the first country in the Middle East to register Sputnik V vaccine". RFID. 11 January 2021. Archived from the original on 5 February 2021. Retrieved 27 January 2021.
"Turkmenistan is the first in Central Asia to have registered "Sputnik V» vaccine". Orient (به انگلیسی). 18 January 2021. Archived from the original on 27 January 2021. Retrieved 27 January 2021.
Chen, Wei; Al Kaabi, Nawal (18 July 2020). "A Phase III clinical trial for inactivated novel coronavirus pneumonia (COVID-19) vaccine (Vero cells)". Chinese Clinical Trial Registry. Archived from the original on 11 October 2020. Retrieved 15 August 2020.
Yang, Yunkai. "A Study to Evaluate The Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above". ClinicalTrials.gov. Archived from the original on 14 September 2020. Retrieved 15 September 2020.
"A Phase III clinical trial for inactivated novel coronavirus pneumonia (COVID-19) vaccine (Vero cells)". chictr.org.cn. Chinese Clinical Trial Register (ChiCTR). Archived from the original on 31 December 2020. Retrieved 15 December 2020.
"Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of SARS-CoV-2 Infection (COVID-19) (Renqiu)". ClinicalTrials.gov. کتابخانه ملی پزشکی ایالات متحده آمریکا. 12 May 2020. NCT04383574. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
"Clinical Trial of Efficacy and Safety of Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine in Healthcare Professionals (PROFISCOV)". ClinicalTrials.gov. کتابخانه ملی پزشکی ایالات متحده آمریکا. 2 July 2020. NCT04456595. Archived from the original on 11 October 2020. Retrieved 3 August 2020.
"Tests show coronavirus vaccine by China's Sinovac is safe, says Brazil's Butantan Institute". Archived from the original on 29 October 2020. Retrieved 29 October 2020.
"Chile initiates clinical study for COVID-19 vaccine". Archived from the original on 11 October 2020. Retrieved 29 October 2020.
"Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial For Evaluation of Efficacy and Safety of SARS-CoV-2 Vaccine (Vero Cell), Inactivated". ClinicalTrials.gov. 8 October 2020. Archived from the original on 20 October 2020. Retrieved 22 October 2020.
Gou, Jinbo. "Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and Above". ClinicalTrials.gov. Archived from the original on 18 September 2020. Retrieved 17 September 2020.
"CanSino's COVID-19 vaccine approved for military use in China". Nikkei Asia. Archived from the original on 7 March 2021. Retrieved 24 December 2020.
"О регистрации вакцины ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора «ЭпиВакКорона»". Rospotrebnadzor (به روسی). 14 October 2020. Archived from the original on 1 November 2020. Retrieved 27 January 2021.
"A Study of Ad26.COV2.S in Adults". ClinicalTrials.gov. 4 August 2020. Archived from the original on 16 September 2020. Retrieved 23 August 2020.
"A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants". ClinicalTrials.gov. US National Library of Medicine. Archived from the original on 26 September 2020.
"Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS (COVID-19) Nanoparticle Vaccine With/Without Matrix-M Adjuvant". ClinicalTrials.gov. کتابخانه ملی پزشکی ایالات متحده آمریکا. 30 April 2020. NCT04368988. Archived from the original on 14 July 2020. Retrieved 14 July 2020.
"A Randomized, Blinded, Placebo-controlled Trial to Evaluate the Immunogenicity and Safety of a Recombinant New Coronavirus Vaccine (CHO Cell) With Different Doses and Different Immunization Procedures in Healthy People Aged 18 to 59 Years". ClinicalTrials.gov. کتابخانه ملی پزشکی ایالات متحده آمریکا. 10 July 2020. NCT04466085. Archived from the original on 28 July 2020. Retrieved 26 August 2020.
"A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults". ClinicalTrials.gov. 26 June 2020. NCT04449276. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
"A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults". ClinicalTrials.gov. 17 August 2020. NCT04515147. Archived from the original on 23 August 2020. Retrieved 28 August 2020.
"A prospective, randomized, adaptive, phase I/II clinical study to evaluate the safety and immunogenicity of Novel Corona Virus −2019-nCov vaccine candidate of M/s Cadila Healthcare Limited by intradermal route in healthy subjects". ctri.nic.in. Clinical Trials Registry India. 15 December 2020. CTRI/2020/07/026352. Archived from the original on 22 November 2020.
Chander, Vishwadha (14 July 2020). "Canada's Medicago begins human trials of plant-based COVID-19 vaccine". National Post. Reuters. Archived from the original on 1 November 2020. Retrieved 14 July 2020.
"SOBERANA 02A". Registro Público Cubano de Ensayos Clínicos. 17 December 2020. Archived from the original on 27 December 2020. Retrieved 22 January 2021.
"SOBERANA 02". Registro Público Cubano de Ensayos Clínicos. 27 October 2020. Archived from the original on 26 January 2021. Retrieved 22 January 2021.
"Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers". ClinicalTrials.gov. کتابخانه ملی پزشکی ایالات متحده آمریکا. 7 April 2020. NCT04336410. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
"Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19". ClinicalTrials.gov. کتابخانه ملی پزشکی ایالات متحده آمریکا. 2 June 2020. NCT04412538. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
"Study of COVID-19 DNA Vaccine (AG0301-COVID19)". ClinicalTrials.gov. کتابخانه ملی پزشکی ایالات متحده آمریکا. 9 July 2020. NCT04463472. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
"About AnGes – Introduction". AnGes, Inc. Archived from the original on 11 October 2020. Retrieved 1 August 2020.
"CTI and Arcturus Therapeutics Announce Initiation of Dosing of COVID-19 STARR™ mRNA Vaccine Candidate, LUNAR-COV19 (ARCT-021) in a Phase 1/2 study". UK BioIndustry Association. 13 August 2020. Archived from the original on 11 October 2020. Retrieved 23 August 2020.
"Ascending Dose Study of Investigational SARS-CoV-2 Vaccine ARCT-021 in Healthy Adult Subjects". clinicaltrials.gov. Archived from the original on 11 October 2020. Retrieved 23 August 2020.
"Safety and Immunity of Covid-19 aAPC Vaccine". ClinicalTrials.gov. کتابخانه ملی پزشکی ایالات متحده آمریکا. 9 March 2020. NCT04299724. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
"About Us". Shenzhen Genoimmune Medical Institute. Archived from the original on 11 October 2020. Retrieved 1 August 2020.
"Immunity and Safety of Covid-19 Synthetic Minigene Vaccine". ClinicalTrials.gov. کتابخانه ملی پزشکی ایالات متحده آمریکا. 19 February 2020. NCT04276896. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
"Safety and Immunogenicity Study of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Adults". ClinicalTrials.gov. کتابخانه ملی پزشکی ایالات متحده آمریکا. 24 June 2020. NCT04445389. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
"S. Korea's Genexine begins human trial of coronavirus vaccine". Reuters. 19 June 2020. Archived from the original on 11 October 2020. Retrieved 25 June 2020.
"SCB-2019 as COVID-19 Vaccine". ClinicalTrials.gov. کتابخانه ملی پزشکی ایالات متحده آمریکا. 28 May 2020. NCT04405908. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
"Clover Biopharmaceuticals starts Phase I Covid-19 vaccine trial". Clinical Trials Arena. 20 June 2020. Archived from the original on 11 October 2020. Retrieved 25 June 2020.
"About Us". Clover Biopharmaceuticals. Archived from the original on 11 October 2020. Retrieved 1 August 2020.
"Monovalent Recombinant COVID19 Vaccine (COVAX19)". ClinicalTrials.gov. کتابخانه ملی پزشکی ایالات متحده آمریکا. 1 July 2020. NCT04453852. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
"Vaxine". Archived from the original on 11 October 2020. Retrieved 1 August 2020.
"A Phase I clinical trial to evaluate the safety, tolerance and preliminary immunogenicity of different doses of a SARS-CoV-2 mRNA vaccine in population aged 18–59 years and 60 years and above". Chinese Clinical Trial Register. 24 June 2020. ChiCTR2000034112. Archived from the original on 11 October 2020. Retrieved 6 July 2020.
"Company introduction". Walvax Biotechnology. Archived from the original on 11 October 2020. Retrieved 1 August 2020.
"A prospective open label randomised phase-I seamlessly followed by phase-II study to assess the safety, reactogenicity and immunogenicity of Biological E's novel Covid-19 vaccine containing Receptor Binding Domain of SARS-CoV-2 for protection against Covid-19 disease when administered intramuscularly in a two dose schedule (0, 28D) to healthy volunteers". ctri.nic.in. Clinical Trials Registry India. 13 January 2021. CTRI/2020/11/029032. Archived from the original on 12 November 2020.
"A Study on the Safety, Tolerability and Immune Response of SARS-CoV-2 Sclamp (COVID-19) Vaccine in Healthy Adults". ClinicalTrials.gov. کتابخانه ملی پزشکی ایالات متحده آمریکا. 3 August 2020. NCT04495933. Archived from the original on 11 October 2020. Retrieved 4 August 2020.
"UQ-CSL V451 Vaccine". precisionvaccinations.com. Archived from the original on 19 December 2020. Retrieved 11 December 2020.

who.int

"Draft landscape of COVID 19 candidate vaccines". World Health Organization. 2020-11-12. Retrieved 2020-11-16.
"Update on WHO Solidarity Trial – Accelerating a safe and effective COVID-19 vaccine". World Health Organization. 2020-04-27. Retrieved 2020-05-02. It is vital that we evaluate as many vaccines as possible as we cannot predict how many will turn out to be viable. To increase the chances of success (given the high level of attrition during vaccine development), we must test all candidate vaccines until they fail. WHO is working to ensure that all of them have the chance of being tested at the initial stage of development. The results for the efficacy of each vaccine are expected within three to six months and this evidence, combined with data on safety, will inform decisions about whether it can be used on a wider scale
"WHO issues its first emergency use validation for a COVID-19 vaccine and emphasizes need for equitable global access". سازمان جهانی بهداشت (WHO) (Press release). 31 December 2020. Retrieved 6 January 2021.

worldcat.org

So, Anthony D; Woo, Joshua (2020-12-15). "Reserving coronavirus disease 2019 vaccines for global access: cross sectional analysis". The BMJ. 371. doi:10.1136/bmj.m4750. ISSN 0959-8138. PMC 7735431. PMID 33323376.
Le, Tung Thanh; Cramer, Jakob P.; Chen, Robert; Mayhew, Stephen (2020-09-04). "Evolution of the COVID-19 vaccine development landscape". Nature Reviews Drug Discovery. 19 (10): 667–68. doi:10.1038/d41573-020-00151-8. ISSN 1474-1776. PMID 32887942. S2CID 221503034.
Thanh Le, Tung; Andreadakis, Zacharias; Kumar, Arun; Gómez Román, Raúl; Tollefsen, Stig; Saville, Melanie; Mayhew, Stephen (9 April 2020). "The COVID-19 vaccine development landscape". Nature Reviews Drug Discovery. 19 (5): 305–306. doi:10.1038/d41573-020-00073-5. ISSN 1474-1776. PMID 32273591.
Zimmer, Carl; Corum, Jonathan; Wee, Sui-Lee (10 June 2020). "Coronavirus Vaccine Tracker". نیویورک تایمز. ISSN 0362-4331. Retrieved 12 December 2020.
Widge, Alicia T.; Rouphael, Nadine G.; Jackson, Lisa A.; Anderson, Evan J.; Roberts, Paul C.; Makhene, Mamodikoe; et al. (3 December 2020). "Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination". New England Journal of Medicine. Massachusetts Medical Society. doi:10.1056/nejmc2032195. ISSN 0028-4793. PMC 7727324. PMID 33270381.
Logunov, Denis Y.; Dolzhikova, Inna V.; Shcheblyakov, Dmitry V.; Tukhvatulin, Amir I.; Zubkova, Olga V.; Dzharullaeva, Alina S.; Kovyrshina, Anna V.; Lubenets, Nadezhda L.; Grousova, Daria M.; Erokhova, Alina S.; Botikov, Andrei G. (2021-02-02). "Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia". The Lancet (به انگلیسی). 0 (0). doi:10.1016/S0140-6736(21)00234-8. ISSN 0140-6736.
Logunov, Denis Y; Dolzhikova, Inna V; others (2020). "Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia". The Lancet. 396 (10255): 887–97. doi:10.1016/s0140-6736(20)31866-3. ISSN 0140-6736. PMC 7471804. PMID 32896291. S2CID 221472251.
Wee, Sui-Lee; Qin, Amy (2020-12-30). "A Chinese Covid-19 Vaccine Has Proved Effective, Its Maker Says". The New York Times. ISSN 0362-4331. Retrieved 2020-12-30.
Zhu, Feng-Cai; Guan, Xu-Hua; Li, Yu-Hua; Huang, Jian-Ying; Jiang, Tao; Hou, Li-Hua; et al. (July 2020). "Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial". Lancet. 396 (10249): 479–88. doi:10.1016/s0140-6736(20)31605-6. ISSN 0140-6736. PMID 32702299. Lay summary. {{cite journal}}: Cite uses deprecated parameter |lay-url= (help)
Rawat, Kajal; Kumari, Puja; Saha, Lekha (24 November 2020). "COVID-19 vaccine: A recent update in pipeline vaccines, their design and development strategies". European Journal of Pharmacology. 892: 173751. doi:10.1016/j.ejphar.2020.173751. ISSN 1879-0712. PMC 7685956. PMID 33245898.

xinhuanet.com

"Myanmar launches nationwide COVID-19 vaccination program". Xinhua News. January 27th 2021. {{cite news}}: Check date values in: |date= (help)
http://xinhuanet.com/english/2021-01/03/c_139637781.htm

yabiladi.com

en.yabiladi.com

https://en.yabiladi.com/articles/details/104807/covid-19-morocco-authorizes-sinopharm-vaccine.html

yahoo.com

finance.yahoo.com

"Panama approves Pfizer's COVID-19 vaccine – health ministry". Yahoo! Finance. Retrieved 16 December 2020.
"ReiThera Announces its GRAd-COV2 COVID-19 Vaccine Candidate is Well Tolerated and Induces Clear Immune Responses in Healthy Subjects Aged 18-55 Years". ReiThera Srl. Yahoo! Finance. 24 November 2020. Retrieved 12 January 2021.